Bayer struggles to turn the page on glyphosate

The German group is dragging the takeover of Monsanto like a ball. He goes on the offensive in gene therapy and precision agriculture.

The controversy around glyphosate is starting again. As the approval of this controversial substance expires in the European Union in December 2022, two reports with contradictory conclusions on its harmfulness have rekindled the heated debates around this herbicide.

A debate of nearly ten years that Bayer, whose subsidiary Monsanto is the world’s leading producer of this weedkiller under the Roundup brand, is following very closely. The German company has still not digested the acquisition in 2018 for $ 63 billion from the American. An operation that turns out to be a real drag. Bayer has lost half of its stock market value in three years and is crumbling under legal proceedings.

He ended the year 2020 in losses of 10.5 billion euros, weighed in particular by the special charges related to the various trials (23.2 billion euros). He had to spend 2 billion euros in provisions related to glyphosate. “Werner Baumann, who was a long-time supporter of this acquisition,

This article is for subscribers only. You have 78% left to discover.

To cultivate one’s freedom is to cultivate one’s curiosity.

Continue reading your article for € 1 for 2 months

Already subscribed? Log in


Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.